ACTG 325: The purpose of this two-part study is to determine the safety and tolerance of several doses of rhIL-12, which will be given under the skin by injection. A total of thirty-six (36) people across the US with CD4 cell counts less than 50 cells/mm3 will participate in Part A, which will involve three different dose levels of rhIL-12 or matching placebo for 4 weeks. A total of twenty-seven (27) people with CD4 cell counts 300-500/mm3 will participate in Part B of the study, which will involve two different dose levels of rhIL-12 or matching placebo for four weeks. A total of 3-4 people will participate at UNC-CH.
Showing the most recent 10 out of 782 publications